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HDN, also known as erythroblastosis fetalis, is an
immune-mediated anemia, caused by maternal
antibodies against a specific fetal RBC antigen. The
advent of Rh immune globulin (RhIG) almost 40 years
ago has decreased the incidence of D-associated HDN.
Maternal isoimmunization to other RBC antigens, for
which there is no prophylaxis, continues to occur. The
frequency of the latter has increased compared with
that of Rh disease. Historically, HDN had a high rate of
perinatal mortality. Advances, including improved
neonatal care, amniocentesis, fetal RBC typing, and in
utero transfusion,have decreased overall fetal loss rates
to 2 to 3 percent.1 Middle cerebral artery Doppler
ultrasound has reduced the need of repetitive
amniocenteses for assessment of fetal anemia.
Determination of free fetal DNA in the maternal
circulation is a new technique that may confirm the D
status of a fetus, and thus is useful in identifying the
fetus, parented by a heterozygous father, who is not at
risk.
Historical Review
HDN was first described in 400 BC by Hippocrates.
In 1609,a French midwife reported a hydropic newborn
girl who expired at birth with a twin who developed
jaundice and neurologic complications and subse-
quently died.2 Throughout the 19th century, the
proposed cause of icterus gravis was the absence or
obstruction of the bile duct. The term erythroblastosis
fetalis connoted a hydropic stillborn by Rautmann in
1912.3 It was not until 1931 that Buhrman and Sanford
made the connection between erythroblastosis fetalis
and newborn jaundice.4 Landsteiner and Wiener
described the Rh factor, and a year later Levine
determined that antibodies against the D antigen were
instrumental in the cause of HDN.5,6 The subsequent 60
years advanced the care of affected pregnancies
including timing of delivery, amniocentesis for fetal
assessment, in utero fetal transfusion, and noninvasive
modalities for determining fetal risk. Improvements
made in the care for this disorder cannot be overstated.
Before 1945, 50 percent of all fetuses with hemolytic
disease died, accounting for 10 percent of overall
perinatal mortality.7
RBC Alloimmunization
The antigens of the Rh system are the most common
cause of immunization during pregnancy. Although
more than 40 antigens belong to this system, D, C, c, E,
and e are the most common. D– blood is found in about
15 percent of Caucasians and 5 percent of Africans.
Other RBC antigens have been identified as the cause of
HDN, including those in the Kell,Duffy, and Kidd blood
group systems. HDN caused by antigens other than D is
increasing in prevalence. The pathogenesis of HDN is
similar, whether the disease is caused by D or another
antigen,and for the purposes of this discussion D will be
used.
A D– pregnant woman exposed to D antigen,usually
as a result of transplacental passage, may develop allo-
immunization. Events that are associated with fetal to
maternal hemorrhage include delivery, abortion, molar
or ectopic pregnancies, and procedures including
amniocentesis,cordocentesis,chorionic villus sampling,
and external cephalic version, as well as trauma and
abruption. The maternal immune response is variable
and is affected by the volume of fetomaternal hemor-
rhage, fetal zygosity for D, and ABO compatibility of
mother and fetus.8 Once a woman has developed D-
specific IgG antibodies, a subsequent fetus is at risk of
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hemolysis if its RBCs exhibit the offending antigen. The
presence and severity of the anemia depend on both the
antibody concentration and prior pregnancy history.
Antibody subtype, frequency of expressed antigen,
efficiency of placental immunoglobulin transport, and
fetal spleen maturity all play a role in fetal RBC
destruction.9
Fetal anemia and resultant extramedullary hemato-
poiesis lead to a reduction of colloid osmotic pressure
and liver congestion, respectively, producing portal
hypertension. The fetus may then develop abnormal
fluid collections,which is termed hydrops. Other RBC
antigens including C, c, E, and e can provoke similar
immune responses.
Initial Workup of an Alloimmunized
Pregnancy
For the purpose of consistency, Rh disease is
described here. Data supporting the management of
alloimmunization to antigens other than D is limited,but
most authorities recommend management similar to
that of D isoimmunization.10
Blood typing and an IAT should be performed on
entry into prenatal care. The presence of a positive
antibody screen suggests alloimmunization and requires
characterization. Determining the antibody specificity,
whether it is to D or another antigen, is necessary for
two reasons: (1) some antibodies are not clinically
significant and are not associated with HDN, and (2)
paternal testing is available for most RBC antigens to
assess for risk of transmission. For example, if the father
is homozygous for D, all his offspring will be D+ and
thus be at risk of HDN. Fifty-five percent of individuals
are heterozygous for the antigen, which decreases the
incidence of the fetus’RBCs being D to 50 percent. The
difficulty with determining paternal zygosity for D is
that no defined allele for the recessive condition has
been identified. Therefore,serology testing for C,c,D,E,
and e combined with ethnicity can provide an estimated
risk of heterozygosity. Paternal testing is more helpful
with other RBC antigens. In these cases, maternal
sensitization may occur owing to a prior transfusion;
thus the potential exists that the partner may not exhibit
the corresponding RBC antigen. After phenotyping of
the parental RBCs is completed, further management is
dependent on the potential for the fetus’RBCs to exhibit
the antigen (Fig. 1).11
If the father’s RBCs are D+ and the couple does not
have a history of an affected child, the patient may be
given one of two options: (1) serial monitoring of
maternal antibody titer on a biweekly or monthly basis
until it reaches a critical value;or (2) offering an amnio-
centesis to investigate fetal D (or any other antigen)
status using PCR.
Fetal DNA from nucleated RBCs has been isolated in
maternal blood and used for fetal RhD genotyping.12 A
recent meta-analysis reported 94.8 percent accuracy of
noninvasive fetal Rh determination using maternal
blood. In alloimmunized pregnancies, 91.8 percent of
the cases were correctly diagnosed. Free fetal DNA in
maternal serum or plasma had higher diagnostic accu-
racy when compared with RNA or DNA extracted from
maternal blood.13 These techniques are currently not
believed to be definitive. The potential error of not
correctly identifying a D+ fetus in an alloimmunized
mother is not completely preventable at present.
Hopefully in the near future such a test will achieve 100
percent accuracy and become the preferred method for
determining fetal D status and eliminating unnecessary
workups for fetuses not at risk for HDN.
Estimating Risk of HDN
HDN is classified as mild, moderate, and severe.14
The majority of cases present as mild, requiring
newborn phototherapy. Only 30 percent of affected
newborns have moderate and 20 percent have severe
Fig. 1. Algorithm for workup in the alloimmunized pregnancy.11
Maternal antibody titer (IAT) > critical value
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disease. Moderate cases have anemia and may require
preterm delivery and exchange transfusion. Fetuses
with severe disease are hydropic. Fortunately, less than
10 percent of patients have severe disease at less than 34
week’ gestational age, the time when in utero therapy
would be necessary. Estimating the risk of HDN relies
on prior history and maternal antibody titer. A patient
without a prior history of sensitization would be
expected to have a good outcome. Conversely,one with
a prior affected pregnancy or certainly a prior hydropic
fetus or adverse postnatal course would be at risk for an
adverse outcome. Antibody titers alone are unreliable
for prediction when a patient has had a prior affected
fetus or infant.
Maternal Antibody Titer
Methods for determining the titer vary by institution,
and the critical value for the potential of fetal anemia is
usually established in each laboratory. A titer between 8
and 32 is considered critical. This applies to Rh as well
as other antigens. The exception is K, in which there
are affected cases when maternal titers are less than 16.
In a pregnancy without a prior affected fetus, the titer is
repeated every 2 to 4 weeks as long as it remains below
the critical threshold. Once the value is met, serial
assessments for the possibility of fetal anemia must be
undertaken,by either amniocentesis or middle cerebral
artery Doppler ultrasound. In cases in which there is a
history of a prior severely affected fetus, serial surveil-
lance is warranted regardless of the antibody titer.
Amniocentesis
Yellow amniotic fluid in anemic fetuses with severe
hemolytic disease correlates with its high bilirubin
content and is likely derived from fetal pulmonary and
tracheal secretions. Liley15 first described, in 1961, a
qualitative analysis of amniotic fluid bilirubin for HDN,
which is measured by spectrophotometry, absorbing
light at a wavelength of 450 nm. The resulting deviation
from baseline (∆OD 450) is plotted against gestational
age (Fig. 2). The graph is divided into three zones with
zone I indicating a low likelihood of severe anemia,zone
II intermediate,and zone III a high probability of severe
fetal anemia. The prediction of fetal anemia requires
repeated samplings every 1 to 3 weeks depending on
the initial value. Decreasing values are reassuring,but a
rising curve indicates active hemolysis. Values in upper
zone II or zone III require further assessment with
cordocentesis to determine fetal hemoglobin or
consideration of delivery if beyond 34 weeks’gestation.
The Liley curve was modified by Queenan using data
from the early second trimester, allowing earlier
diagnosis and treatment of fetal anemia in pregnancy.16
Amniotic fluid PCR can be used to document the
fetal antigen status for D and other common antigens.17
A number of blood banks provide this testing, usually
requiring amniotic fluid or cultured amniocytes and
parental blood. A fetus subsequently found lacking the
gene that encodes the antigen requires no further
workup or monitoring. Amniocentesis is not without
risks. The common complications include infection and
preterm membrane rupture. Furthermore, it may poten-
tially cause an anamnestic maternal immune response,
placing the fetus at further risk of anemia.
Ultrasound
During the past 20 years investigators have at-
tempted to use ultrasound to indirectly screen for fetal
anemia as a result of the concerns about amniocentesis
complications. Parameters that can be monitored by
ultrasound include umbilical vein diameter, fetal spleen
or liver length, biventricular outer diameter, and
placental thickness. Unfortunately,most of these poorly
predict fetal anemia, and their use in current clinical
practice is limited.18 The only validated tool for fetal
anemia prediction is middle cerebral artery Doppler
ultrasound. Anemic fetuses have increased cardiac out-
put, decreased blood viscosity, and thus increased flow
velocity. Mari et al.19 in 2000 showed that measurement
of peak systolic velocity in the middle cerebral artery
accurately predicts severe fetal anemia (Fig.3). Once the
Fig. 2. Liley curve. Optical density at 450 nm is measured (∆OD-450) and
plotted against gestational age.15
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critical antibody screening titer has been achieved,
cerebral Doppler ultrasounds are performed on a
weekly or biweekly basis. When peak systolic values
reach 1.5 times the median of those expected for
gestational age, cordocentesis is indicated for deter-
mining fetal hemoglobin level,blood type,and potential
intrauterine transfusion. After 35 weeks’ gestation this
modality becomes less reliable,and there is an increased
false-positive rate.20 Depending on the clinical history,
consideration should be given to documenting fetal lung
maturity and determining the ∆OD 450 via amnio-
centesis at around 36 weeks.
Recently in a multicenter trial of detection of severe
fetal anemia, Doppler ultrasound and amniotic fluid
∆OD 450 were compared for sensitivity and accuracy.
Results revealed that Doppler was more sensitive and
accurate when compared with ∆OD 450 using the Liley
method and was as sensitive and accurate when
compared with Queenan’s method.21 The conclusion of
the trial was that Doppler can safely replace the more
invasive amniocentesis for detection of fetal anemia.
Intrauterine Fetal Transfusion
Intrauterine peritoneal blood transfusion using x-ray
guidance was first described by Liley in 1963.22 Since
this groundbreaking step toward intrauterine treatment
of fetal anemia, many modifications of the procedure
have been made with the hope of improving the safety
of the procedure. The purpose of fetal transfusion is to
reestablish normal fetal hematocrit with donor RBCs
that lack the offending antigen(s) and suppress subse-
quent fetal bone marrow production. Donor blood is
group O, D–. The blood is packed to a Hct of 75% to
80%, is screened for infections including CMV, and is
irradiated to prevent graft-versus-host reactions. The
amount of transfused blood depends on pretransfusion
and desired posttransfusion hematocrits (usually 45–
50%), gestational age, and hematocrit of the donor.23
Transcutaneous approaches can be either fetal
intraperitoneal or intravascular, and both performed
under ultrasound guidance. Intraperitoneal transfusion
places the donor blood into the fetal peritoneal cavity
and relies on the absorption of the RBCs via the
subdiaphragmatic and thoracic ducts. The utility of this
method is limited in fetuses with hydrops because the
absorption into the lymphatics is impaired and is
associated with a higher fetal death rate. Intravascular
access has the advantage of direct and immediate
delivery of donor RBCs into the fetal vasculature. Both
the umbilical vein and the intrahepatic vein have been
used for access. Exact placement to some extent
depends on fetal and placental position, ease of access
to the cord root, and operator training. Free loops of
cord are avoided because of the potential of tearing with
fetal movement.
The timing of fetal blood sampling and potential
transfusion can be challenging. The goal is to initiate the
process once the fetus has moderate to severe anemia
but before development of hydrops. Intravascular fetal
transfusion is now considered to be a safe procedure
with an overall survival rate of 89 percent and
procedure-related rate of loss of 1.6 percent per
procedure. Complications such as rupture of mem-
branes, intrauterine infection, emergency cesarean
section, fetal death, and neonatal death have been
reported.24
Timing of Delivery and Intrapartum Issues
The fetal risks of HDN increase as gestation
advances. Therefore an alloimmunized pregnancy is
preferably delivered before the estimated due date.
Actual timing of the delivery should be dictated by the
estimated severity of disease, balancing the risks of
ongoing hemolysis and need for in utero transfusion
versus the risks of prematurity. Patients with mild or
moderate disease usually are delivered at around 36 to
37 weeks, after confirmation of fetal lung maturity.
Severely affected fetuses are usually delivered when the
risks of transfusion outweigh the risks of long-term
disability from a preterm birth, or if one can estimate
the need for transfusion based on the last known fetal
hematocrit after 34 weeks. If an atypical antibody is
detected, the woman’s blood sample should be typed
and crossmatched once labor occurs. Delivery should
Fig. 3. Peak systolic velocity in the middle cerebral artery of pregnancies
at risk for fetal anemia. Open circles indicate no fetal anemia or
mild anemia. Triangles indicate moderate to severe anemia. Solid
circles indicate fetuses with hydrops.19
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be preferably at an institution adept at caring for
neonates with the possibility of severe anemia.
Conclusion
RhIG, Doppler ultrasonography, and intrauterine
fetal transfusion have improved the care of pregnancies
affected by D or isoimmunization by other antigens
including K. Once thought to be a fatal disease, in utero
severe fetal anemia can now be reversed with about 90
percent survival rate. The care of a mother affected by
RBC alloimmunization can be challenging and time-
consuming, especially in cases in which fetal RBC
antigen type is unknown. The hope is that within the
next decade advances in determination of free fetal DNA
in the maternal blood will significantly improve care and
avoid many unnecessary procedures.
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